By Jessica Fino
Date: Tuesday 05 Aug 2014
LONDON (ShareCast) - Venn Life Sciences, a clinical research organisation (CRO), announced on Tuesday the acquisition of Cardinal Systems SAS, a French CRO specialising in Data Management.
The acquisition will allow Venn to extend its service of clinical trial management and resourcing solutions.
The company will by September own 85.2% of the enlarged share capital of Cardinal.
Venn has subscribed €200,000 of new ordinary shares and has purchased existing shares in Cardinal for €272,780.
Venn's chief executive Tony Richardson said the acquisition "enhances our growth opportunities as a company as we can target a wider portfolio of studies and we have already encountered positive feedback from potential customers".
JF
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 27.25p |
Change Today | -0.25p |
% Change | -0.91 % |
52 Week High | 30.50p |
52 Week Low | 14.25p |
Volume | 601,061 |
Shares Issued | 680.37m |
Market Cap | £185.40m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 3 |
Buy | 3 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 6 |
Latest | Previous | |
---|---|---|
Final | Special | |
Ex-Div | 18-Apr-24 | 04-May-23 |
Paid | 20-May-24 | 09-Jun-23 |
Amount | 0.20p | 0.45p |
Time | Volume / Share Price |
16:29 | 10,000 @ 27.24p |
16:29 | 2,000 @ 27.24p |
16:17 | 366 @ 27.28p |
16:09 | 6,250 @ 27.28p |
16:05 | 56,100 @ 27.00p |
You are here: research